
Zanidatamab Is a Breakthrough in HER2- Positive Biliary Tract Cancer Treatment
The recent FDA approval of zanidatamab-hrii (Ziihera; Jazz Pharmaceuticals) marks a pivotal moment in the treatment of unresectable or metastatic HER2-positive (HER2+) biliary tract cancer (BTC). With its dual HER2-targeting mechanism, zanidatamab has …